Bicycle Therapeutics plc American Depositary Shares

The global Peptide Drug Conjugate (PDC) market is projected to reach $1.5 billion by 2031, growing at over 14% CAGR from 2021-2025. PDCs offer targeted drug delivery solutions for oncology and other diseases with reduced systemic toxicity. The market features over 50 clinical candidates and 18 proprietary technologies, with major players includin...

Bicycle Toxin Conjugates (BTCs) are emerging as a novel targeted oncology technology, offering innovative peptide-based drug delivery with potential applications in cancer treatment and beyond, with early clinical trials showing promising results.

Maxion Therapeutics appointed Dr. Santiago Arroyo as a Non-Executive Director, bringing extensive clinical development expertise from roles at multiple pharmaceutical and biotech companies.

The advanced urothelial carcinoma market is witnessing significant growth, driven by an aging population and the rising prevalence of metastatic cases. Advances in immunotherapy and targeted treatments are transforming the treatment landscape, with over 20 key companies developing new therapies.

Here is how Bicycle Therapeutics PLC Sponsored ADR (BCYC) and Twist Bioscience (TWST) have performed compared to their sector so far this year.